Chapter 104: Prenatal Drug Use: Neonatal Effects and the Neonatal Withdrawal Syndrome
Enrique M. Ostrea, Jr, MD, Josef Cortez, MD, FAAP, Neil Joseph B. Alviedo, MD, Felix De Paz Bañadera, MD, Lilia C. De Jesus, MD, FAAP, Charlie Tan Cheng, MD, 2016. "Prenatal Drug Use: Neonatal Effects and the Neonatal Withdrawal Syndrome", American Academy of Pediatrics Textbook of Pediatric Care, Thomas K. McInerny, MD, FAAP, Henry M. Adam, MD, FAAP, Deborah E. Campbell, MD, FAAP, Thomas G. DeWitt, MD, FAAP, Jane Meschan Foy, MD, FAAP, Deepak M. Kamat, MD, PhD, FAAP, Rebecca Baum, MD, FAAP, Kelly J. Kelleher, MD, MPH, FAAP
Download citation file:
Updated on September 28, 2020
Few barriers exist to the passage of most drugs across the placenta or to their biotransformation in the placenta into inactive or active drug metabolites.1,2 Maternal substance use during pregnancy increases the risk of complications such as stillbirth, meconium-stained amniotic fluid, premature rupture of the membranes, maternal hemorrhage (abruptio placenta or placenta previa), and fetal distress.3 Newborns exposed to drugs in utero experience greater morbidity and mortality than other neonates. Problems include increased rates of asphyxia; preterm birth; low birth weight; infections, including sexually transmitted infectious diseases; pneumonia; congenital malformations; cerebral...